4-hydroxyphenylpyruvate dioxygenase
آخر تحديث 18 Aug 2020
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- Ask Patient
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
ال HPD gene provides instructions for making an enzyme called 4-hydroxyphenylpyruvate dioxygenase. This enzyme is abundant in the liver, and smaller amounts are found in the kidneys. It is second in a series of five enzymes that work to break down the amino acid tyrosine, a protein building block found in many foods. Specifically, 4-hydroxyphenylpyruvate dioxygenase converts a tyrosine byproduct called 4-hydroxyphenylpyruvate to homogentisic acid. Continuing the process, homogentisic acid is further broken down and ultimately smaller molecules are produced that are either excreted by the kidneys or used to produce energy or make other substances in the body.
اختيارات الفيديو لـ Genesمكتبة الفيديو
Normal function
ال HPD gene provides instructions for making an enzyme called 4-hydroxyphenylpyruvate dioxygenase. This enzyme is abundant in the liver, and smaller amounts are found in the kidneys. It is second in a series of five enzymes that work to break down the amino acid tyrosine, a protein building block found in many foods. Specifically, 4-hydroxyphenylpyruvate dioxygenase converts a tyrosine byproduct called 4-hydroxyphenylpyruvate to homogentisic acid. Continuing the process, homogentisic acid is further broken down and ultimately smaller molecules are produced that are either excreted by the kidneys or used to produce energy or make other substances in the body.
Conditions referring to this gene or chromosome
Other names
4-HPPD
4HPPD
GLOD3
HPPD_HUMAN
P-hydroxyphenylpyruvate hydroxylase
P-hydroxyphenylpyruvate oxidase
PPD
Related patient information and medicines

Patient information leaflet
هل يمكنني تناول ألوجليبتين وريبيلسوس معًا؟
Taking alogliptin and Rybelsus (semaglutide) together can significantly increase the risk of your blood sugar dropping too low (hypoglycaemia). Alogliptin (a DPP-4 inhibitor) prevents the breakdown of natural hormones that lower blood sugar, while Rybelsus (a GLP-1 receptor agonist) mimics those same hormones. Clinical guidelines usually recommend.

Patient information leaflet
قرحة الاثني عشر
A duodenal ulcer is usually caused by an infection with a germ (bacterium) called Helicobacter pylori ( H. pylori ). A 4- to 8-week course of acid-suppressing medication will allow the ulcer to heal. In addition, a one-week course of two antibiotics plus an acid-suppressing medicine will usually clear the H. pylori infection. This usually prevents.

Patient information leaflet
قصور المبيض المبكر
قصور المبيض المبكر is sometimes called premature ovarian failure. The condition occurs when your ovaries no longer work properly when you are under the age of 40 years. Your ovaries no longer produce normal amounts of oestrogen and therefore may not produce eggs. This means that your periods stop (or become irregular) and you may.

Patient information leaflet
هل يمكنني تناول السيلدينافيل والجريب فروت معًا؟
Drinking grapefruit juice or eating grapefruit while taking sildenafil can significantly increase the amount of the medicine in your bloodstream. Why this happens Your body uses a specific enzyme (called CYP3A4) in the gut and liver to break down sildenafil. Our Medicines Interaction Checker helps you check whether your prescriptions,.

Patient information leaflet
هل يمكنني تناول مكملات الألياف والميتفورمين معًا؟
Taking fibre supplements at the same time as metformin may slightly lower the amount of medicine your body absorbs. Our مدقق تفاعلات الأدوية helps you check whether your prescriptions, over-the-counter medicines, and supplements يكون آمن إلى take together. إخلاء المسؤولية This information is for general educational purposes only and should not.

Patient information leaflet
مرض ويلسون
مرض ويلسون is a genetic disorder in which copper builds up in the body, mainly in the liver and brain.
قراءة إضافية ومراجع
- 4-hydroxyphenylpyruvate dioxygenase; MedlinePlus, National Library of Medicine.
- Aarenstrup L, Falch AM, Jakobsen KK, Neve S, Henriksen L LO, Tommerup N, Leffers H, Kristiansen K. Expression and post-translational modification of human 4-hydroxy-phenylpyruvate dioxygenase. Cell Biol Int. 2002;26(7):615-25. doi: 10.1006/cbir.2002.0896.
- Brownlee JM, Heinz B, Bates J, Moran GR. Product analysis and inhibition studies of a causative Asn to Ser variant of 4-hydroxyphenylpyruvate dioxygenase suggest a simple route to the treatment of Hawkinsinuria. Biochemistry. 2010 Aug 24;49(33):7218-26. doi: 10.1021/bi1008112.
- Ellaway CJ, Holme E, Standing S, Preece MA, Green A, Ploechl E, Ugarte M, Trefz FK, Leonard JV. Outcome of tyrosinaemia type III. J Inherit Metab Dis. 2001 Dec;24(8):824-32. doi: 10.1023/a:1013936107064.
- Heylen E, Scherer G, Vincent MF, Marie S, Fischer J, Nassogne MC. Tyrosinemia Type III detected via neonatal screening: management and outcome. Mol Genet Metab. 2012 Nov;107(3):605-7. doi: 10.1016/j.ymgme.2012.09.002. Epub 2012 Sep 7.
- Ruetschi U, Cerone R, Perez-Cerda C, Schiaffino MC, Standing S, Ugarte M, Holme E. Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III. Hum Genet. 2000 Jun;106(6):654-62. doi: 10.1007/s004390000307.
- Tomoeda K, Awata H, Matsuura T, Matsuda I, Ploechl E, Milovac T, Boneh A, Scott CR, Danks DM, Endo F. Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria. Mol Genet Metab. 2000 Nov;71(3):506-10. doi: 10.1006/mgme.2000.3085.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
18 Aug 2020 | أحدث إصدار
1 Jan 2008 | نُشر في الأصل
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.

